ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 2499

Influence of Adiposity on Physical Function, Physical Activity, and Self-Reported Symptom Severity for Individuals with Arthritis Prior to Beginning a Physical Activity Promotion Intervention
Abstract Number: 2500

Suicidal Ideation and Self-Efficacy in Systemic Lupus Erythematosus: Georgians Organized Against Lupus (GOAL) Cohort
Abstract Number: 2501

Selection of Indicators Reporting Response Rate in Pharmaceutical Trials for Systemic Lupus Erythematosus: Preference and Relative Sensitivity
Abstract Number: 2502

Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus
Abstract Number: 2503

Cytokines Regulate the Fibrotic Response of Growth Factors in Joint Fibroblast-like Synoviocytes
Abstract Number: 2504

The Effect of Inflammatory Conditions on the Regulation of Canonical and Non-canonical NF-kB Pathways via Bcl11b
Abstract Number: 2505

Discovery of First-in-Class IRAK4 Scaffolding Inhibitors for the Treatment of Inflammatory Disorders
Abstract Number: 2506

Role of TGF-β Activated Kinase 1 in Cytokine-Driven Juvenile Idiopathic Arthritis Synovial Fibroblasts Activation
Abstract Number: 2507

ZCCHC6 Modulates the Global Phosphorylation Landscape in TNF-a-induced Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2508

Chronic IL-6 Trans-Signaling Enhances Stem Cell-Like Characteristics of Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 2509

Risk Factors and Mortality of Immune Checkpoint Inhibitor-Induced Flares of Pre-Existing Rheumatoid Arthritis: An Analysis Accounting for Competing Risk of Death and Immortal Time Bias
Abstract Number: 2510

Autoantibody-positivity Before Treatment Is Associated with Immune-related Adverse Events in Melanoma Patients Treated with anti-PD-1
Abstract Number: 2511

Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies
Abstract Number: 2512

Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis
Abstract Number: 2513

Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].